EMA Review Of Non-EU Drugs To Be Made More Useful For African Regulators
Executive Summary
The European Medicines Agency is looking into how it can better promote the Article 58 procedure under which it evaluates the quality, safety and efficacy of medicines or vaccines intended for use outside the EU. The procedure has been underutilized by industry to date and the EMA wants to encourage its use, especially for drugs to be used in Sub-Saharan Africa.
You may also be interested in...
EMA Brings Non-EU Regulators Into CHMP Meetings
The European Medicines Agency is continuing with its plans to involve non-EU regulators in scientific reviews. It notes in its 2016 activity report that Israeli regulators for the first time took part in a CHMP meeting.
Could The EMA Be A Regulatory Model For East Africa?
A meeting between the European Medicines Agency and representatives of the East African Community discussed whether the European agency could act as a model for a regulator in the six-country region.
African Regulatory Harmonization Project Cuts Drug Approval Times And Saves Scarce Resources
A pilot project of joint assessments in East Africa has shown that regulatory review times for a number of branded medicines were reduced from one or two years to a median of seven months, representing a reduction of 40-60%. The project was part of the African Medicines Regulatory Harmonization initiative, which is intended to strengthen and align regulatory practices in sub-Saharan Africa. Part one of this article looks at the history of the AMRH, the 2016 Model Law that guides national regulators in implementing their own procedures, and the East African pilot that has shown joint reviews to be feasible at the regional level.